StockData
BioAge Labs, Inc. logo

BioAge Labs, Inc. (BIOA) stock

BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$5.10−0.12 (-2.30%)

Close on Nov 17, 2026Market cap $234.07MP/E –Yield –

BioAge Labs cash

Cash and short-term investments held at the end of each period.

BioAge Labs's cash was $318.75M at Jun 30, 2026. For fiscal 2025 it was $281.10M, down 20.7% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$281.10M-20.7%
FY2024Dec 31, 2024$354.35M+1537.2%
FY2023Dec 31, 2023$21.64M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$318.75M+7.2%
Q1 FY2026Mar 31, 2026$383.19M+19.6%
Q4 FY2025Dec 31, 2025$281.10M-20.7%
Q3 FY2025Sep 30, 2025$285.78M-14.6%
Q2 FY2025Jun 30, 2025$297.30M+70.9%
Q1 FY2025Mar 31, 2025$320.52M+1380.9%
Q4 FY2024Dec 31, 2024$354.35M–
Q3 FY2024Sep 30, 2024$334.47M–
Q1 FY2024Mar 31, 2024$173.99M–
Q4 FY2023Dec 31, 2023$21.64M–

More BioAge Labs figures

See a number that looks wrong?